Keywords: Umeclidinium; GSK573719; COPD; Single dose; Repeat dose;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA
Keywords: Combination therapy; COPD; Inhaled corticosteroids; Long-acting bronchodilators; LAMA/LABA; Fixed-dose dual bronchodilators; CDS; Chronic Disease Score; CI; confidence interval; COPD; chronic obstructive pulmonary disease; ER; emergency room; FDC; fixed-d
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi
Keywords: Umeclidinium (PubChem CID: 11519070); vilanterol (PubChem CID: 10184665); umeclidinium/vilanterol (PubChem CID: 71300746); Umeclidinium; Vilanterol; Fixed dose combination; Synergistic interaction; Isolated bronchi; COPD;
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study
Keywords: Asthma; Chronic obstructive pulmonary disease; Inhaled corticosteroids; Long-acting muscarinic antagonist; Umeclidinium; AE; adverse event; AESI; AEs of special interest; ANCOVA; analysis of covariance; CI; confidence interval; COPD; chronic obstructive p
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies
Keywords: Long-acting muscarinic antagonist; Inhaled corticosteroid; Long-acting beta2 agonist; Bronchodilation; AE; adverse event; ASE; all subjects enrolled; CAT; COPD Assessment Test; CI; confidence interval; COPD; chronic obstructive pulmonary disease; FEV1; fo
A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD
Keywords: AE; adverse event; FSC; fluticasone propionate/salmeterol; ICS; inhaled corticosteroid; LABA; long-acting Ã2-agonist; LAMA; long-acting muscarinic antagonist; MCID; minimal clinically important difference; NNTB; number needed to treat for benefit; SAE; s
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
Keywords: COPD; Fluticasone propionate; Salmeterol; Umeclidinium; Vilanterol;
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
Keywords: Chronic obstructive pulmonary disease; GSK573719; QT interval; Umeclidinium; Vilanterol
Efficacy and safety of umeclidinium/vilanterol 62.5/25Â mcg and tiotropium 18Â mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial
Keywords: Long-acting bronchodilator; Umeclidinium; Vilanterol; AE; adverse event; CI; confidence interval; COPD; chronic obstructive pulmonary disease; DPI; Dry powder inhaler; FEV1; forced expiratory volume in one second; FP; fluticasone propionate; FVC; forced v
Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study
Keywords: chronic obstructive pulmonary disease; GSK573719; long-acting β2-agonist; long-acting muscarinic antagonist; umeclidinium; vilanterol;
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients
Keywords: Chronic obstructive pulmonary disease; Long-acting muscarinic receptor antagonist; Long-acting bronchodilator; Anticholinergic; Umeclidinium; GSK573719
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: A randomized placebo-controlled trial
Keywords: COPD; LAMA; LABA; Umeclidinium; GSK573719; VilanterolAE, adverse event/s; AUC, area under the curve; bpm, beats per minute; CI, confidence interval; Cmax, maximum plasma concentration; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; F